Lilly's Web-Based Research Marketplace
This article was originally published in Start Up
Executive Summary
Eli Lilly & Co. is venturing into previously uncharted e-R&D waters with Innocentive LLC, a wholly owned subsidiary launched earlier this summer with an undisclosed amount of backing. Innocentive offers a means for pharmaceutical and other research-dependent companies to farm out research problems to scientists who receive cash awards of up to $100,000 from any company that accepts a particular solution.
You may also be interested in...
Armed With An FDA-Cleared IND, TLS Sets Out To Democratize Clinical Trials
Transparency Life Sciences applies crowdsourcing to the design of clinical protocols with the aim of lowering costs and improving outcomes for clinical trials. The company won FDA clearance for its first IND based on a protocol that resulted from its process and is securing its first financing.
Lilly's Chorus Experiment
With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?
Lilly's Chorus Experiment
With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?